Cargando…

Inflammatory Markers and Outcomes in Cardiovascular Disease

In a commentary on two new research studies in PLoS Medicine, Leonard Kritharides discusses the role of inflammatory markers in predicting cardiovascular outcomes and patients' responses to treatment.

Detalles Bibliográficos
Autor principal:	Kritharides, Leonard
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730031/ https://www.ncbi.nlm.nih.gov/pubmed/19901972 http://dx.doi.org/10.1371/journal.pmed.1000147

Ejemplares similares

Association between pre-existing cardiovascular disease, mortality and cardiovascular outcomes in hospitalised patients with COVID-19
por: Sritharan, Hari P., et al.
Publicado: (2023)

Erectile Dysfunction Severity as a Risk Marker for Cardiovascular Disease Hospitalisation and All-Cause Mortality: A Prospective Cohort Study
por: Banks, Emily, et al.
Publicado: (2013)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Cardiovascular and Logistic Issues Associated With COVID-19 Pandemic
por: Robert Denniss, A., et al.
Publicado: (2020)

Does HIV Cause Cardiovascular Disease?
por: Carr, Andrew, et al.
Publicado: (2006)

Cardiovascular Disease: The Other Face of Diabetes
por: Vlasakakis, G, et al.
Publicado: (2013)

Energy metabolism homeostasis in cardiovascular diseases
por: WANG, Lu-Yun, et al.
Publicado: (2021)

Acylations in cardiovascular diseases: advances and perspectives
por: Chen, Xiaofeng, et al.
Publicado: (2022)

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Cardiovascular disease: The rise of the genetic risk score
por: Knowles, Joshua W., et al.
Publicado: (2018)

Flavonoids and Their Metabolites: Prevention in Cardiovascular Diseases and Diabetes
por: Zeka, Keti, et al.
Publicado: (2017)

Canagliflozin and Cardiovascular disease- results of the CANVAS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Normalizing the dementia status in cardiovascular diseases: a perspective
por: Frisardi, Vincenza
Publicado: (2022)

Mental stress, meditation, and yoga in cardiovascular and cerebrovascular diseases
por: Fayyaz, Aminah I., et al.
Publicado: (2023)

Advances in the management of cardiovascular risk for patients with type 2 diabetes: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes
por: Schernthaner, Guntram, et al.
Publicado: (2017)

Inflammatory Bowel Disease in Asia: The Challenges and Opportunities
por: Hu, Pin-Jin
Publicado: (2015)

Clearing of the Clouds in Inflammatory Bowel Disease Management
por: Costrini, Nicholas V.
Publicado: (2020)

Heterogeneous genetic architecture by gender for precision medicine of cardiovascular disease
por: Lee, Chaeyoung
Publicado: (2018)

Digital health for primary prevention of cardiovascular disease: Promise to practice
por: Narla, Akhila, et al.
Publicado: (2020)

Mitochondrial Telomerase Reverse Transcriptase, a Target for Cardiovascular Disease?
por: Torimoto, Keiichi, et al.
Publicado: (2022)

Know Your Variability: Challenges in Mechanistic Modeling of Inflammatory Response in Inflammatory Bowel Disease (IBD)
por: Rogers, Katharine V., et al.
Publicado: (2017)

Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study
por: West, Malcolm, et al.
Publicado: (2022)

Connecting the Dots: Structural Racism, Intersectionality, and Cardiovascular Health Outcomes for African, Caribbean, and Black Mothers
por: Baiden, Deborah, et al.
Publicado: (2022)

Short Sleep Duration Is Associated with Risk of Future Diabetes but Not Cardiovascular Disease: a Prospective Study and Meta-Analysis
por: Holliday, Elizabeth G., et al.
Publicado: (2013)

Potential benefits of Chinese Herbal Medicine for elderly patients with cardiovascular diseases
por: Luo, Jing, et al.
Publicado: (2013)

H(2)S and Oxytocin Systems in Early Life Stress and Cardiovascular Disease
por: McCook, Oscar, et al.
Publicado: (2021)

The urgent need for a policy on epidemiological data on cardiovascular diseases in Bangladesh
por: Proma, Amrin Yeasin, et al.
Publicado: (2023)

Oral microbiome: a doubtful predictor but potential target of cardiovascular diseases
por: Cheng, Chak Kwong, et al.
Publicado: (2023)

Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives
por: Zhou, Jun, et al.
Publicado: (2021)

Cocoa Polyphenols and Inflammatory Markers of Cardiovascular Disease
por: Khan, Nasiruddin, et al.
Publicado: (2014)

Inflammatory Markers for Arterial Stiffness in Cardiovascular Diseases
por: Mozos, Ioana, et al.
Publicado: (2017)

Elevated Erythritol: A Marker of Metabolic Dysregulation or Contributor to the Pathogenesis of Cardiometabolic Disease?
por: Mazi, Tagreed A., et al.
Publicado: (2023)

Understanding cardiovascular disease: a journey through the genome (and what we found there)
por: Lara-Pezzi, Enrique, et al.
Publicado: (2012)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease
por: Gao, Shen, et al.
Publicado: (2017)

Developing cardiovascular disease risk programs in India—Why location and wealth matter
por: Peiris, David, et al.
Publicado: (2018)

Role of Serum Amyloid A in Abdominal Aortic Aneurysm and Related Cardiovascular Diseases
por: Shridas, Preetha, et al.
Publicado: (2021)

Cardiovascular Disease in Diabetes
por: Bloomgarden, Zachary T.
Publicado: (2010)

The four epidemiological stages in the global evolution of inflammatory bowel disease
por: Kaplan, Gilaad G., et al.
Publicado: (2020)

Immune-mediated inflammatory disease therapeutics: past, present and future
por: McInnes, Iain B., et al.
Publicado: (2021)

Integrative systems of genomic risk markers for cancer and other diseases: future of predictive medicine
por: Yuzhalin, Arseniy E, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_l6uha99ndedp8p5h61p8u0pdi2